Business Context and Reporting Period
This Form 8-K filing by Bluelinx Holdings Inc. covers the period ending July 31, 2015. The report addresses a regulatory notification received from the New York Stock Exchange (NYSE) regarding the Company's stock price compliance.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data point disclosed is the stock price performance:
- 30-Day Average Closing Price: $0.99 per share (as of July 27, 2015).
- NYSE Minimum Requirement: $1.00 per share average over 30 consecutive trading days.
Material Changes
The primary material event is the receipt of a notice from the NYSE on July 29, 2015, stating that the Company failed to satisfy the continued listing rule (Rule 802.01C) due to the average closing price of its common stock falling below $1.00 for 30 consecutive trading days.
Outlook, Management Commentary, and Risks
- Cure Period: The Company has six months from the date of notification to regain compliance.
- Compliance Strategy: Management intends to actively monitor the share price and is considering available options, including equity-based actions such as a reverse stock split, to resolve the deficiency.
- Operational Impact: The notice has no immediate impact on the listing status (stock continues to trade under symbol "BXC"), business operations, or SEC reporting requirements.
- Debt Covenants: The notification does not conflict with or cause an event of default under any material debt or other agreements.
Investor Verification Checklist
- Verify the current trading price of BXC to assess the likelihood of regaining compliance within the six-month window.
- Monitor future announcements for the execution of a reverse stock split or other capital structure changes.
- Confirm that the stock price remains above $1.00 on the last trading day of any calendar month during the cure period to meet the specific NYSE reinstatement criteria.